Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Myhealthchecked Plc | LSE:MHC | London | Ordinary Share | GB00BN7K5L93 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 12.50 | 0.00 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 12.00 | 13.00 | 12.50 | 12.50 | 12.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 10.98M | -159k | -0.0031 | -40.32 | 6.5M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 12.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/10/2024 | 10:12 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 26/9/2024 | 14:04 | ALNC |  EARNINGS AND TRADING: Touchstar mulls strategic options as profit down |
| 26/9/2024 | 06:00 | UK RNS | MyHealthChecked PLC Half-year Report |
| 24/9/2024 | 09:47 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 20/9/2024 | 10:21 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 12/9/2024 | 06:00 | UK RNS | MyHealthChecked PLC Notice of Results |
| 28/6/2024 | 09:54 | UK RNS | MyHealthChecked PLC Result of AGM |
| 04/6/2024 | 15:41 | ALNC | EARNINGS AND TRADING: Hummingbird loss narrows as revenue climbs |
| 04/6/2024 | 06:00 | UK RNS | MyHealthChecked PLC Final Results & Notice of AGM |
| 22/5/2024 | 06:00 | UK RNS | MyHealthChecked PLC Notice of Results |
Myhealthchecked (MHC) Share Charts1 Year Myhealthchecked Chart |
|
1 Month Myhealthchecked Chart |
Intraday Myhealthchecked Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 18/11/2024 | 08:28 | MyHealthChecked PLC to 100p | 10,231 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Myhealthchecked Daily Update Myhealthchecked Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker MHC. The last closing price for Myhealthchecked was 12.50p.Myhealthchecked currently has 52,005,932 shares in issue. The market capitalisation of Myhealthchecked is £6,500,742. Myhealthchecked has a price to earnings ratio (PE ratio) of -40.32. This morning MHC shares opened at 12.50p |
Posted at 27/10/2024 08:13 by tia01 DualWe know MHC has big plans and clearly in the middle of a deal that is game changing. It will clearly involve Boots and possibly government changes to pharmacy first products available to be used in stores with Boots specialists. The Poc Doc deal is significant also as it will also be sold over the counter or off the shelf. It’s all suggesting that one of the biggest killers in heart disease is a major focus so I personally see heart tests being added to the pharmacy first list. I could be wrong but the government know Boots with MHC tests and digital data can solve the GP appointment problems. Save costs and more efficient and save lives. MHC are focusing on LFT tests IMO which is why they ain’t restocked VITAMIN D tests as no margins in them. I also see a surprise and do wonder if Newfoundland may try a cheap takeover of MHC. They already supply the LFT tests and HIV tests to Boots via MHC!. They are also in many major shops but can’t get in Boots without MHC who have the required approval as you pointed out. Boots is extremely strict which is why it hasn’t stocked the prostrate tests because of the trauma it could cause after a positive test result etc. I think this may change as it’s a big issue. Chris Hoy a true ambassador and legend highlighting the need for more testing is testament to why Boots and MHC need to combine to offer a testing service to the public for NHS patients. Also note many black Caribbean suffer prostrate issues so Boots and MHC could use marketing to target the ethnic communities by highlighting this!. Anyway don’t expect and deal until the new year because of the parties involved and complexity involved. I do anticipate a market campaign to start in November to coincide with the run up to Christmas and the deal that will be announced in the new year hopefully. The focus on Covid revenue has clearly shifted towards testing and the question is can MHC get the revenue breaking deal done without a share dilution required!. I think the answer is 100 YES but equally a VAT refund will ensure the answer is yes. Also note Directors can’t buy until the deal is announced. Once again will Newfoundland be ambitious and smart enough to launch a strike for MHC knowing the potential benefits to both parties. Would MHC make a play for Newfoundland!!!! |
Posted at 26/9/2024 18:57 by tia01 I don’t know how low it goes but today’s sell off triggered a lot of negatives. Unless it bounces back tomorrow it could easily drift back to 12p or less. I’m positive about MHC longer term but the bears have been rampant today which is such a shame.I wish the news regarding boots had been delivered because we were so close to a breakout that could have seen us move towards 20s. The question is why Penny released results knowing they would impact share price without releasing details of the exciting news she proclaimed on LinkedIn in recently. That’s truly crazy because surely Boots and MHC given the relationship can agree terms to sign it off or does it involve a third party such as NHS deal!. Extremely bad timing for results however tomorrow will be interesting to see what happens after today |
Posted at 11/9/2024 18:02 by tia01 I seriously don’t think Penny believes there’s any money in LFT tests other than Covid ones.Fact is I’m Sure Newfoundland provide MHC with its LFT tests so I guess it’s hard for MHC to compete with them on those tests. MHC clearly focused on phlebotomy testing and I feel a deal with Boots to supply tests for NHS patients. GPs have made the government realise they need a new approach otherwise waiting lists will get even longer and waiting time also. I just feel the share price is suffering as a result of the wait for news. I don’t know what the value of Newfoundland is but could a Merger with MHC really make sense given one is focused more on LFT and the other phlebotomy tests. Time for Penny to deliver something really exciting to share so we can all go to the River Wye to celebrate lol. |
Posted at 29/8/2024 07:05 by tia01 Muck166So it looks like ABDX raised another 500k through share placement. 80%?take up but no Directors participation. Raised at decent share price with little to no discounts. It’s definitely an interesting market for MHC given MHC has self funded growth plan. If MHC can demonstrate growth in new products and a profit generating use for the digital data investment then this could easily re rate inline with ABDX. Crucial to see what’s said in update due. Need a deal with Boots to offer phlebotomy testing and possibly a an expansion of products offered on pharmacy first and we move up quickly. A lot to wish for but Penny must deliver as cash don’t last forever unless we have a plan for growth of new products |
Posted at 27/8/2024 11:32 by muck166 Tia - I don't want to get in a spat with you about valuations, especially on the MHC board. And I am not saying MHC is a bad company - it isn't.Yes, ABDX supplies Boots with some own label tests. In fact, they are exactly the same Chinese tests that MHC also sell through Boots, just in different packaging. And yes, ABDX makes and sells pregnancy tests, as well as other tests. But even a cursory look at its accounts will show you that revenue it makes from total product sales is less than 10% of its total revenue. The bulk of its revenue comes from CDMO/CRO activities on a fee for service model, ie it helps third party lateral flow developers move an idea to a commercial, approved LFT product that can be manufactured at scale and robustly. That is its main business, and its NOT the same as MHC. I don't know why MHC has an MCAP of less than ABDX, but if I were to guess I would say it's because MHC remains heavily reliant on COVID revenue (which is falling) and seems to be stagnating rather than growing, whereas ABDX has growing revenue from a multitude of different customers and streams, as well as some huge potential in its pipe. There are very good reasons why 3 institutional investors took almost all of the recent raise at less than a 10% discount - I assume it's because they see real growth potential in ABDX. Sadly, MHC isn't showing investors anything at the moment. |
Posted at 19/8/2024 14:46 by tia01 SpacedustThis time it could be different because we have a CEO who has worked alongside LYN Rees. So will know how to get a deal done with NCYT 100%. Remember Penny mentioned phlebotomy testing in the investor meeting and spoke about a deal with Boots. Said she hoped to announce News within a few months nearly 3 months ago. We know MPOX tests have to be administered by a professional health expert hence the importance of a deal with Boots instore testing. We also know the government will welcome testing in Boots because GPs have cut appointments and emergency wards over run. MPOX could have been the game changer we are looking for. I’m sure Penny is fully aware. I’d also love to see other announcements also. This is definitely an opportunity I doubt Penny will miss. I recall her saying she was really interested in LFT tests when PCR testing ended and I said she’s smart enough to change that strategy and she did. I believe she’s extremely talented as is aware a deal with Boots and NCYT moves the share price North rapid. Thus allowing the share price to be used as leverage for any further acquisitions etc |
Posted at 19/8/2024 13:07 by spacedust Mhc was valuable physically during the pandemic but as an investor this has been battered to the gutters. The share price was much higher without hardly any income.But now we have contracts galore with 1600% rise in profits the share price has declined very badly and there's no respite despite record breaking turnover |
Posted at 14/8/2024 09:07 by tia01 SpacedustYou are 100% wrong in my opinion. A dividend just appeases shareholders short term. A buyback using capital earned off interest would be utilising funds to take shares off the open market and increase earnings per share moving forward. 10% buyback would cost around half a million but remove 5m shares from the open market! Thus leaving 47m in circulation of which a third is tied up by large long term holders. This would be hugely positive and positive. Create a demand for very few shares leading to an increase in share price. Supply and demand. Also remember they have the shares which then can be put back on the market if shares increase in value which appears to have already happened this morning. It’s possible with the last two months Covid sales that MHC have over 9m in cash and earnings interest at 4%. Debt free and can buyback shares without using borrowed cash. Amazing situation in my opinion. Then possible news as alerted to in investor meeting could easily see a huge rerate. |
Posted at 30/6/2024 08:52 by tia01 I took this morning to read the Chairman’s Statement and it’s clear a slowdown is expected in Covid tests in the first half of 2024.Is it all bad news! I personally see a slowdown that will see sales of Covid for first six months of 2024 to come in at around 3m based on 1 test being sold in each of the 1900 stores nationwide and also online sales during the period. You may think ouch but as stated in Chairman’s statement a decline is expected. The good thing is it’s evident the other tests provided by MHC will make up for lost revenue from the Covid tests as sales increase. I don’t expect a huge amount of revenue from new tests but it’s reasonable to expect between half a million and three quarters in the first half. So I would anticipate a similar overall figure to the first half in 2023 with combined sales and wellness tests. The key will be any update that may lead to an anticipated huge uptick in wellness test sales in Boots. We are expanding to another 200plus stores with wellness tests however this will come at a cost to MHC for the initial costs of shelving and stock etc. It will however add to the long term growth of revenue. It’s also self funded. I do expect strong cost control to reserve cash and also believe any collaboration with Boots pharmacy first and phlebotomy testing privately within Boots instore MOT services available could provide a catalyst needed. I don’t think a buy back will be announced although it would be a great idea. I believe the company will prioritise using cash for growing the business instead. I believe MHC should use Tik Tok content creators who advertise for free and at a cost of MHC sending a free sample to demonstrate. Of course MHC would need to sell the products on TIk Tok shop in order for content creators to access them and offer free promotions. TIk Tok viewers are probably between 16 to 40 but many of the tests are geared towards these ages and then we must remember that all these 18-40s have older family members they may buy a test for. Remember if you give a free test to 20 Tik Tok members who each have 20,000 plus followers for example that a potential sale to 400,000 off just 20 free samples! Times this by 50 free samples etc you see how quick it would be to get the brand out there for literally nothing. Then you have the benefits of being on TIK TOK shop. This would be great if they have a deal with Boots and use Tik Tok viewers to make people aware of the products and services etc. It would also help encourage direct sales to MHC and enhance the user rate of the digital data. MHC must be smart a use the 8m of cash wisely to gain traction to wellness tests which are the future of the business whilst Covid revenue is this available. Covid revenue is the key to growth without dilution and valuable for MHC. A recent surge in Covid cases will reflect in 2nd half results in my opinion as Boots will buy tests in advance based on the figures and projections to ensure they are stocked for winter 2024 and summer 2024. The market will only react to news flow from MHC which is expected imminently. Penny has a great opportunity to demonstrate the future of wellness testing combined with the importance of digital data which Poc Doc has demonstrated is the future |
Posted at 19/6/2024 21:15 by tia01 SpacedustI do share your view. Penny is smart enough to realise no real money in LFT £7.99p tests. Phlebotomy tests is collaboration with Boots will bring about change. Possibly more tests added to pharmacy first to help relieve pressure off GPs etc. COVID revenue still steady and seasonal. Digital Data to help large companies and insurance companies etc. Look at Poc Doc and you’ll understand the way forward is digital data which Penny invested in heavily. Peoples habits will change however it will take time and investment which is why COVID revenue is vital. If deals are done and RNS prior to half year update we could see a sharp rise as people see potential huge revenue growth. Then we have products going into 200 more stores so it’s clear the strategy is Boots and Pharmacy first and instore testing. Dont under estimate how smart Penny is. She was smart enough to make money from Covid and probably the smartest thing was to continue with the Covid tests which have driven cash and enabled self funded growth. Is it painful to watch the share price doing title!. Yes 100%. I’d love a small buyback to encourage new money to follow and Directors to buy also but we need to see. A 10% buyback would cost the company £500,000 however we would probably see 50% jump in share price which would be the best investment for MHC. Sometimes buying your own stock is better than an acquisition in the long run if you believe in your business strategy. I truly believe in Penny and do believe her hands are tied ATM because of Boots a regulation on news. Client confidentiality etc. Fingers crossed for all LTHs but stay the course and add more if you have cash at these levels in my opinion |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
